Atyr Pharma Inc

This management proposal asks shareholders to ratify the Audit Committee’s appointment of Ernst & Young LLP (EY) as the company’s independent registered public accounting firm for fiscal 2026. Management seeks shareholder ratification as a matter of good corporate practice even though the appointment is not legally required; EY has been the auditor since 2008 which management cites to support continuity and familiarity with the company’s financials. The Audit Committee describes fees paid to EY and confirms pre-approval policies for audit and non-audit services; the Board states it values shareholder feedback and will consider any significant negative vote though the Audit Committee retains discretion to continue the engagement. The recommendation is “FOR” because the Board and Audit Committee deem EY qualified and independent, view ratification as usual market practice, and because maintaining the incumbent auditor preserves audit continuity and reduces transition costs and risks. Investors evaluating the proposal should weigh auditor tenure and any auditor fees or non-audit engagements disclosed against governance considerations like recent audit committee oversight and the company’s responses to material audit findings (none disclosed here). The proposal is routine and likely to be uncontroversial absent concerns revealed in the financial statements or auditor communications.

This management proposal requests a non-binding advisory approval of the Company’s named executive officer compensation as disclosed in the proxy statement. Management frames compensation as aligned to business objectives and market practice, with significant at-risk elements (bonuses and equity awards) to align pay with performance. The Board and Compensation Committee emphasize that they will consider the outcome in future decisions though the vote is not binding. Given recent clinical trial results (Phase 3 EFZO-FIT did not meet primary endpoint but showed signals) and the Compensation Committee’s decision to reduce bonus payout from 75% to 60%, investors will evaluate whether pay appropriately reflects performance. The Board recommends a vote FOR, arguing that their compensation structure incentivizes long-term value creation and retention of key executives. Sophisticated investors should weigh the apparent balance between fixed and at-risk pay, disclosed bonuses and option grants, and the Compensation Committee’s responsiveness to trial outcomes when evaluating the proposal.

This management proposal requests shareholder approval for a share reserve increase in the Company’s 2015 Stock Option and Incentive Plan by 4,000,000 shares (to 19,725,101). Management argues the increase is necessary to continue to grant equity incentives to employees, directors and consultants to attract, retain and motivate talent, particularly as the company advances efzofitimod through late-stage development and prepares for potential commercialization. The proposal notes that approximately 68% of outstanding employee options are underwater and that overhang would rise from 15.9% to 19.9% if approved; management also explains that they manage dilution via targeted burn-rate policies and monitoring. The plan’s substantive terms (no repricing without shareholder approval, inclusion of various award types, change-in-control provisions, and recapture of forfeited shares) aim to limit potential governance concerns. Investors should evaluate the incremental dilution, the company’s historical grant practices, the concentration of awards among executives, and whether the increased reserve is justified by hiring and retention needs versus alternative compensation mechanisms. The Board recommends a FOR vote, emphasizing the plan’s role in long-term value creation and retention.

This management proposal requests shareholder approval to amend the charter to double the authorized common stock to 340 million shares. Management frames the increase as a strategic measure to provide flexibility for financing, collaborations, acquisitions, equity compensation and other corporate purposes, and notes there are currently no specific plans to issue the additional shares. The filing discloses the current outstanding and reserved share counts, showing approximately 55.1 million unissued and unreserved shares prior to the 2015 Stock Plan increase. Management warns that approval could facilitate defensive measures (e.g., selling shares to oppose hostile takeovers) though it says the proposal was not prompted by any takeover threat. The Board recommends a FOR vote, arguing that insufficient authorized shares could constrain capital-raising, transaction and compensation flexibility and adversely affect the company’s growth prospects. Investors should consider potential dilution and governance risks associated with a large increase in authorized shares, the company’s capital needs, and the lack of pre-commitments to issue shares, weighing flexibility benefits against shareholder dilution and takeover defense concerns.